Please assess the completion status of the following clinical trial:

Trial Title: STA-21 Topical Efficacy on Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A history of plaque psoriasis for a minimum of 2 years.~* In good general health, as evidenced by blood, renal function, and liver function tests conducted before commencing the study.~* Patients of childbearing age who agreed to continue using birth control for the duration of the study.~* Men or women between 20 and 80 years old.~Exclusion Criteria:~* Chronic plaque psoriasis involving \>40% of the body surface.~* Pustular or generalized erythrodermic psoriasis.~* Use of medications that might affect the psoriasis during the study~* Systemic therapy for psoriasis within 60 d of baseline.~* UV therapy within 21 d of baseline.~* Topical therapy within 14 d of baseline.~* Positive for HIV, hepatitis B, or hepatitis C.~* Clinically significant laboratory abnormality in blood, renal function, or liver function.~* Lactating, pregnant, or planning to become pregnant.~* Participation in another clinical trial in the last 30 d.~* Unwillingness to comply with the study protocol.~* Any other condition that in the opinion of the investigators could compromise the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Psoriasis therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).